Related by context. All words. (Click for frequent words.) 71 multivariate analyzes 69 prognostic factor 69 prognostic variables 68 covariates 68 comorbidities 67 nodal metastases 67 comorbidity 66 covariate 66 biochemical recurrence 65 univariate 65 multivariable analysis 65 confounders 65 Subgroup analyzes 64 tumor histology 64 multivariate logistic regression 64 confounding variables 64 Multivariate analysis 64 Logistic regression 64 lymph node metastases 64 histological subtype 64 prognostic indicators 63 lymph node metastasis 63 univariate analysis 63 neoadjuvant 63 histologic 63 lymphadenectomy 63 adjuvant therapy 63 renal tumors 63 distant metastasis 63 regression analyzes 63 comorbid conditions 62 univariate analyzes 62 breast carcinoma 62 prognostic significance 62 preoperatively 62 multivariate analysis 62 sonographic findings 62 preoperative 62 neoplasm 62 mRNA expression 62 lymph node involvement 62 KRAS mutations 62 distant metastases 62 logistic regression analysis 62 HRQL 62 multivariate Cox 62 logistic regression models 62 potential confounders 62 subgroup analyzes 62 contralateral breast cancer 62 hormone receptor status 62 locoregional 61 T1a 61 androgen deprivation 61 F FDG PET 61 prostate cancer CaP 61 plain radiographs 61 carotid IMT 61 urothelial carcinoma 61 genetic polymorphisms 61 logistic regression analyzes 61 node metastases 61 APOE genotype 61 adjuvant chemotherapy 61 pancreatic adenocarcinoma 61 histologies 61 clinicopathological features 61 sociodemographic variables 61 oncologic outcomes 61 explanatory variables 61 prognostic indicator 61 FDG PET 61 liver transplant recipients 61 radical nephrectomy 60 Baseline characteristics 60 endocrine therapy 60 prostate cancer PCa 60 clinically localized prostate 60 mucinous 60 prospectively defined 60 HNSCC 60 metabolic parameters 60 histologic subtype 60 clinicopathological 60 hamartomas 60 KRAS status 60 intima media thickness 60 Kaplan Meier analysis 60 histological subtypes 60 Logistic regression analysis 60 PCa 60 multivariable analyzes 60 pulmonary metastases 60 intact parathyroid hormone 60 locoregional recurrence 60 neurocognitive function 60 advanced adenomas 60 progesterone receptor PR 60 logistic regression model 60 clinicopathologic 60 poorer prognosis 60 coronary stenosis 60 subclinical hypothyroidism 59 histopathologic 59 perioperative complications 59 estrogen receptor ER 59 genotypic resistance 59 HER2 expression 59 telomere lengths 59 axillary lymph nodes 59 adjuvant therapies 59 postoperative complication 59 Poisson regression 59 prognostic markers 59 intravesical therapy 59 preoperative chemotherapy 59 liver histology 59 karyotypes 59 Kaplan Meier curves 59 Recurrence Score 59 pT3 59 endometrial carcinoma 59 prognostic 59 virologic responses 59 Univariate 59 nodal metastasis 59 myocardial viability 59 nonmetastatic 59 malignant lesions 59 epithelial tumors 59 ALND 59 baseline LDH 59 ECOG 59 lymphovascular invasion 59 operable breast cancer 59 SLNB 59 microsatellite instability 59 adenomatous polyps 59 SUVmax 59 extracapsular extension 59 tumor recurrence 59 logistic regression 59 preoperative PSA 59 susceptibility loci 59 breast cancer subtypes 59 conditional logistic regression 59 neoadjuvant chemotherapy 59 familial clustering 59 multivariate regression analysis 59 radical cystectomy 59 histopathological 59 CTEPH 59 EGFR mutations 59 histologic subtypes 59 posttransplant 59 etiologic 58 pCR 58 IL#B 58 nonoperative treatment 58 NMIBC 58 immunohistochemical staining 58 pT2 58 Hematologic 58 bivariate 58 Secondary endpoints 58 postoperative mortality 58 neurocognitive impairment 58 Subgroup analysis 58 nephron sparing surgery 58 EBRT 58 serum PSA 58 pelvic lymphadenectomy 58 gene polymorphisms 58 posttreatment 58 perioperative morbidity 58 MetS 58 neoplasms 58 subclinical atherosclerosis 58 neovascular glaucoma 58 brain metastases 58 atypical hyperplasia 58 serous ovarian cancer 58 neoplastic 58 tumor necrosis 58 surrogate markers 58 P = .# 58 lymph node dissection 58 TOP2A 58 vertebral fracture 58 HRQOL 58 proband 58 beta blocker therapy 58 virologic response 58 myocardial ischemia 58 PSADT 58 microalbuminuria 58 nondiabetic patients 58 adenomatous 58 chemoradiation 58 biochemical markers 58 hematologic toxicity 58 cystectomy 58 juvenile idiopathic arthritis 58 odds ratios ORs 58 stage IIIB 58 chemoradiotherapy 58 contralateral breast 58 gastric carcinoma 58 ABCB1 58 QoL 58 Prognostic factors 58 ischemic lesions 58 autonomic dysfunction 58 mammographic density 58 prognostic marker 58 symptomatic VTE 58 EGFR mutation status 58 LVEF 58 elevated LDH 58 obstructive coronary artery 58 extensive metabolizers 57 neurodevelopmental outcome 57 laboratory abnormalities 57 VUR 57 sociodemographic factors 57 HBeAg negative 57 depressive symptomatology 57 sociodemographic 57 FOLPI 57 mycophenolate mofetil 57 renal artery stenosis 57 prostate carcinoma 57 nonrandomized 57 psychosocial functioning 57 astrocytomas 57 alexithymia 57 nonfatal MI 57 radiographic findings 57 metastases 57 cytoreductive surgery 57 infarcts 57 epithelial ovarian cancer 57 papillary 57 acetabular dysplasia 57 IV NSCLC 57 ECOG PS 57 randomized trials 57 morphologic 57 kidney allograft 57 cytogenetic abnormalities 57 Observational studies 57 phenotype 57 exploratory endpoints 57 lymphopenia 57 Multiple logistic regression 57 clinico pathological 57 carcinoid 57 pericardial effusion 57 histologically 57 thyroid nodules 57 confounding factors 57 thromboembolic events 57 adenoma 57 RECIST Response Evaluation Criteria 57 Multivariate logistic regression 57 androgen suppression 57 left ventricular systolic 57 subanalysis 57 DAS# scores 57 lymphadenopathy 57 parathyroidectomy 57 laterality 57 co morbidities 57 stepwise logistic regression 57 affective psychosis 57 immunohistochemical 57 aortic insufficiency 57 BRCA2 mutation carriers 57 proteinuria 57 coronary calcification 57 angiographically 57 Framingham Risk Score 57 etiologies 57 SCr 57 adenocarcinomas 57 central corneal thickness 57 colorectal adenoma 57 psychiatric comorbidity 57 axillary lymph node 57 adjuvant radiotherapy 57 confidence intervals CIs 57 CR nPR 57 predictor variables 57 colorectal neoplasia 57 perinatal outcomes 57 radical prostatectomy 57 advanced adenoma 57 normal karyotype 57 biochemical abnormalities 57 lipid abnormalities 57 endometrial thickness 57 albumin excretion rate 57 resectable 57 interobserver reliability 57 hyperbilirubinemia 57 differentially expressed genes 57 gadolinium enhanced 57 pathologic 57 CLBP 57 graft dysfunction 57 axillary lymph node dissection 57 haematological 57 macrovascular disease 57 prognostically 57 radical prostatectomy RP 57 subtrochanteric 57 primary aldosteronism 57 Univariate analysis 57 adenotonsillectomy 57 carcinomas 57 taxane therapy 57 ovarian carcinoma 57 stratifying patients 57 prognostic biomarker 57 thromboembolic 56 sonographic appearance 56 parenchymal 56 Radical prostatectomy 56 rCBF 56 intraobserver 56 squamous histology 56 axillary node dissection 56 sleeve lobectomy 56 malignant lymphoma 56 MACCE 56 rs# [001] 56 completely resected 56 interobserver 56 euthymic patients 56 definite stent thrombosis 56 timepoints 56 T2DM 56 nonoperative 56 radiotherapy RT 56 proportional hazards 56 perioperative mortality 56 neoadjuvant therapy 56 hallux valgus 56 carotid stenosis 56 underwent resection 56 CC genotype 56 leiomyomas 56 meningiomas 56 unfavorable prognostic 56 thrombophilia 56 postoperative AF 56 precursor lesions 56 MADRS score 56 sentinel lymph node biopsy 56 BRCA2 carriers 56 Secondary efficacy endpoints 56 lipid lowering agents 56 lymphocytosis 56 neoplasias 56 myeloproliferative diseases 56 postoperative chemotherapy 56 Multivariate analyzes 56 chronicity 56 GISTs 56 preoperative diagnosis 56 gastric cancers 56 nulliparous women 56 HSCT 56 parathyroid 56 seminomas 56 mutational status 56 haematologic 56 EGFR inhibitors 56 lymphoproliferative disorders 56 K ras mutations 56 liver metastasis 56 thymoma 56 spirometric 56 TACE 56 carcinoids 56 multiple logistic regression 56 Preoperative 56 BRCA1 mutations 56 DMARD 56 molecular subtypes 56 cervical lymph nodes 56 coronary angiography 56 obstructive CAD 56 cTnT 56 secondary efficacy endpoints 56 pathologic fractures 56 histopathologic examination 56 cervical intraepithelial neoplasia 56 Bonferroni correction 56 unfavorable cytogenetics 56 serum markers 56 antiplatelet therapy 56 heavily pretreated patients 56 supratentorial 56 postoperative radiotherapy 56 abdominal adiposity 56 meta analyzes 56 artery stenosis 56 MMSE score 56 angiographic outcomes 56 serum creatinine levels 56 lobular carcinoma 56 pharmacodynamic parameters 56 gefitinib 56 serum concentrations 56 immunostaining 56 metastatic RCC 56 postoperative pulmonary 56 tertile 56 Thal Dex 56 FDG-PET/CT 56 hamartoma 56 nephrectomy 56 urolithiasis 56 HRQoL 56 hip BMD 56 TT genotype 56 CVD mortality 56 hepatocellular carcinomas 56 esophageal squamous cell carcinoma 56 predictors 56 neoadjuvant treatment 56 serum vitamin D 56 specific antigen PSA 56 renal function 56 noncalcified 56 varicocele 56 VKORC1 56 cytologic 56 ERBB2 56 TEAEs 56 EGFR mutation 56 multivariable logistic regression 56 affective disorders 56 differentiated thyroid 56 extrapyramidal symptoms 56 abnormal glucose tolerance 56 hydronephrosis 56 malignancies 56 unmeasured confounders 56 SNP rs# [002] 56 atherogenic dyslipidemia 56 sarcomatoid 56 antihypertensive therapy 56 rheumatoid factor 56 thromboembolic complications 56 Kruskal Wallis test 56 primary hyperparathyroidism 56 MGUS 56 hemorrhagic complications 56 metabolic abnormalities 56 nonresponders 56 surrogate marker 56 variance ANOVA 56 paragangliomas 56 nomograms 56 systolic hypertension 56 renal dysfunction 56 Leydig cell 56 somatic symptoms 56 patient subpopulations 56 grade cervical intraepithelial 56 rs# [004] 56 hyperplastic 56 nonmelanoma skin cancers 56 medically inoperable 56 tertiles 56 FDG uptake 56 allele frequencies 56 MMSE scores 56 mediastinal 56 progression TTP 56 patients undergoing CABG 56 estrogen receptor progesterone receptor 56 metastatic tumors 56 neurodevelopmental outcomes 56 adverse cytogenetics 56 extramedullary 56 BCR ABL mutations 55 essential thrombocythemia 55 stenoses 55 invasive carcinoma 55 calculi 55 macroalbuminuria 55 BMI z 55 chemotherapeutic regimens 55 cardiovascular morbidity 55 histologically confirmed 55 decompensated cirrhosis 55 grade gliomas 55 Charlson comorbidity index 55 bladder carcinoma 55 pretest probability 55 platelet reactivity 55 BMD measurements 55 external beam radiotherapy 55 gene expression profiles 55 affective psychoses 55 transvaginal sonography 55 lymphoma subtypes 55 echocardiographic parameters 55 gastric atrophy 55 LUTS 55 neurodevelopmental impairment 55 elevated IOP 55 pathophysiological mechanisms 55 paricalcitol 55 % CI #.#-#.# [003] 55 IDH1 mutation 55 HRCT 55 chorioamnionitis 55 pulmonary nodules 55 incomplete revascularization 55 Metastases 55 colorectal adenomas 55 biopsy Gleason 55 thyroglobulin 55 bronchopulmonary dysplasia BPD 55 NIHSS score 55 myocardial perfusion 55 adenoma recurrence 55 CYP#D# genotype 55 micrometastasis 55 genotypic 55 cytoreductive nephrectomy 55 juvenile idiopathic arthritis JIA 55 aetiology 55 monozygotic 55 FDG PET scans 55 metastatic lymph nodes 55 probands 55 syndromal 55 therapeutic regimens 55 papillary RCC 55 adjuvant systemic 55 lymphocytic 55 INCB# [003] 55 pneumonectomy 55 thromboembolic disease 55 HbA 1c levels 55 Meta analyzes 55 IKZF1 55 ADPKD 55 serum testosterone 55 HAQ DI 55 cTnI 55 GnRH agonists 55 NNRTI resistance 55 BRCA mutations 55 premenopausal 55 stage IIIb IV 55 acetabular fracture 55 cytogenetic response 55 KRAS mutation 55 CIN3 55 resected 55 Taxus Stent 55 lobular cancer 55 trials RCTs 55 post thrombotic syndrome 55 renal insufficiency 55 System IPSS 55 troponins 55 polyarticular 55 esophageal carcinoma 55 transurethral resection 55 scintigraphy 55 recurrent glioblastoma multiforme 55 cancer mCRC 55 tHcy 55 sociodemographic characteristics 55 ependymomas 55 Postoperative 55 5 HTTLPR 55 nomogram 55 composite endpoint 55 comorbid disorders 55 HCV genotype 55 thyroid carcinoma 55 echocardiographic 55 K ras mutation 55 cardiac biomarkers 55 osteopenic 55 carotid plaques 55 LV dysfunction 55 tirofiban 55 Doxil ® 55 Sjögren syndrome 55 Preoperatively 55 glomerular filtration rate 55 % CI #.#-#.# [006] 55 MDRD 55 vesicoureteral reflux 55 adrenalectomy 55 rs# [002] 55 renal cell carcinomas 55 CHD mortality 55 hyperintensities 55 Adjuvant chemotherapy 55 Hurthle cell 55 extracranial 55 metastatic lesions 55 elevated serum creatinine 55 symptomatic intracerebral hemorrhage 55 endophenotypes 55 revascularization procedures 55 atopic 55 tumoral 55 SLN biopsy 55 RTOG 55 cardiac dysfunction 55 pheochromocytoma 55 MYCN amplification 55 detrusor overactivity 55 carcinoid tumors 55 metachronous 55 morbidities 55 comorbid depression 55 CIN2 + 55 nondepressed 55 ultrasonographic 55 thromboprophylaxis 55 contralateral 55 poor metabolizers 55 osteochondromas 55 estimated glomerular filtration 55 BMI ≥ 55 vascular dysfunction 55 retrospective cohort 55 postoperatively 55 reintervention 55 sentinel node biopsy 55 retransplantation 55 coronary artery stenosis 55 advanced neoplasia 55 OPCAB 55 resections 55 virologic failure 55 subpopulations 55 penetrance 55 catheter angiography 55 hepatic metastases 55 hemodynamics 55 carcinoid tumor 55 femoral neck fracture 55 psychiatric comorbidities 55 monozygotic twins 55 predisposing factors 55 familial aggregation 55 soft tissue sarcomas 55 subscales 55 breast carcinomas 55 lung metastasis 55 CYP#C# [001] 55 allelic 55 conventional angiography 55 seminal vesicle invasion 55 TNM staging 55 arthrodesis 55 ischemic cardiomyopathy 55 nevi 55 graft occlusion 55 coronary revascularization 55 metaplasia 55 bone scintigraphy 55 socioeconomic status 55 myelosuppression 55 multivariate adjustment 55 microvascular complications 55 adnexal mass 55 CsA 55 glycemia 55 intra abdominal abscess 55 liver metastases 55 cranial irradiation 55 haematopoietic 55 hemodynamically significant 55 cystic lesions 55 lung carcinomas 55 HBeAg positive 55 hypopituitarism 54 hsCRP levels 54 virological response 54 osteochondroma 54 cellularity 54 malignant nodules 54 deletion 5q 54 ERCC1 54 parous women 54 IPAH 54 urine cytology 54 NYHA class 54 acute leukemias 54 QTc prolongation 54 gastric adenocarcinoma 54 cytoreduction 54 methylation patterns 54 papillary renal cell carcinoma 54 multivariable Cox 54 ductal breast cancer 54 colorectal liver metastases 54 PsA 54 MDRD equation 54 morphometric vertebral fractures 54 alanine aminotransferase ALT 54 p = #.# [003] 54 genetic determinants 54 hormone receptor negative 54 metastatic HRPC 54 undetectable HBV DNA 54 lipid parameters 54 reflux esophagitis 54 thromboembolism 54 carotid intima media 54 EDSS scores 54 imatinib therapy 54 sirolimus eluting stents 54 cerebral infarction 54 bowel resection 54 FEV ^ sub 54 CCyR 54 dyssynchrony 54 nonalcoholic steatohepatitis NASH 54 coronary artery calcium 54 antiangiogenic therapy 54 carotid artery stenosis 54 schwannomas 54 karyotype 54 debulking surgery 54 neoplastic lesions 54 residual confounding 54 pleural effusion 54 albuminuria 54 ventricular dysfunction 54 % CI #.#-#.# [007] 54 Randomized trials 54 estrogen receptor negative 54 invasive coronary angiography 54 inflammatory biomarkers 54 glycated hemoglobin levels 54 recurrent miscarriage 54 Socioeconomic status 54 pretransplant 54 recurrent VTE 54 meta regression 54 leukopenia 54 aminotransferase levels 54 adiposity 54 stage IIIA 54 NAFLD 54 potentially confounding variables 54 femoral neck BMD 54 LV ejection fraction 54 Inhibin B 54 chronic pancreatitis 54 preoperative staging 54 coronary calcium 54 MR spectroscopy 54 TRUS 54 metastatic renal cell carcinoma 54 bivariate analysis 54 antihypertensive medications 54 Coronary artery calcium 54 methotrexate therapy 54 femoral shaft fracture 54 dyslipidaemia 54 radiochemotherapy 54 nonischemic 54 atherosclerotic disease 54 left ventricular dysfunction 54 confounder 54 immunosuppressive regimen 54 imatinib 54 myeloproliferative neoplasms 54 osteoid 54 T1 weighted images 54 radiographic outcomes 54 curative resection 54 proximal femur 54 histologically proven 54 neurocognitive deficits 54 antigen PSA 54 PNH patients 54 subclinical hyperthyroidism 54 tumor subtypes 54 monoclonal gammopathy 54 hypoperfusion 54 structural abnormalities 54 waist circumference WC 54 surrogate endpoint 54 RECIST criteria 54 postoperative morbidity 54 clinical endpoints 54 hypercholesterolemia 54 CYP#D# 54 adrenal function 54 potentially modifiable 54 pelvic lymph node dissection 54 hepatic lesions 54 hematopoietic cancers 54 HIV HCV coinfected 54 femoral fracture 54 peritoneal carcinomatosis 54 median PFS 54 HNPCC 54 scintigraphic 54 Montgomery Åsberg Depression 54 hypertensives 54 Liver biopsy 54 comorbid 54 ependymoma 54 macrosomia 54 dosage regimens 54 cystatin C 54 periprocedural 54 cholangiocarcinoma 54 FDG PET imaging 54 hypoxemia 54 physiologic parameters 54 QTc 54 polygenic 54 glomerular filtration 54 colorectal polyps 54 hemiarthroplasty 54 histology 54 serum prostate 54 metastatic bone 54 Thrombolysis 54 coronary stenoses 54 EUS FNA 54 β blockers 54 Estrogen Receptor 54 grade glioma 54 CTNNB1 54 postintervention 54 intraventricular hemorrhage 54 urothelial cancer 54 5-fluorouracil/leucovorin 54 immunohistochemical analysis 54 MLH1 54 HER2 positive metastatic breast 54 liver biopsies 54 lobular carcinomas 54 androgen deficiency 54 hematologic 54 fluvastatin 54 mixed hyperlipidemia 54 CaP 54 adolescent idiopathic scoliosis 54 underlying pathophysiology 54 BRCA1 mutation carriers 54 coinfected patients 54 POAG 54 squamous 54 Kaplan Meier method 54 evaluable patients 54 androgen ablation 54 Response Evaluation Criteria 54 glycoprotein IIb IIIa inhibitors 54 fasting insulin 54 PSA nadir 54 noncardiac 54 deCODE BreastCancer TM 54 LVNC 54 ANCOVA 54 malignant pleural mesothelioma 54 thyroid nodule 54 liver resection 54 leiomyoma 54 PTPN# 54 partial nephrectomy 54 lipid profiles 54 overt hypothyroidism 54 incidentalomas 54 -#.# ± [002] 54 demographic variables 54 HER2 amplification 54 neoplasia 54 homozygotes 54 pathologic fracture 54 hepatic fibrosis 54 events MACE 54 hepatocellular carcinoma HCC 54 ratio WHR 54 cytotoxic chemotherapy 54 VADT 54 acute coronary syndromes ACS 54 intestinal metaplasia 54 pulmonary metastasis 54 hydroxyvitamin D levels 54 reoperation 54 thyroid hormone levels 54 SNHL 54 Primary endpoints 54 HER2 positive cancers 54 pilocytic astrocytomas 54 hsCRP 54 PSA velocity 54 amenorrhoea 54 EGFR HER2 54 Expanded Disability Status 54 standard chemotherapy regimens 54 oophorectomy 53 plasma lipid 53 hypothalamic pituitary adrenal axis 53 premalignant 53 proton MR spectroscopy 53 echogenicity 53 NSTE ACS 53 transferrin saturation 53 metastatic disease 53 Kaplan Meier estimates 53 atheroma volume 53 Index CDAI 53 Kaplan Meier curve 53 SYNTAX trial 53 HbA 1c 53 predictive biomarker 53 cytopenias 53 nonfasting triglyceride levels 53 basal cell carcinoma BCC 53 Solid Tumours 53 Computed tomography 53 recurrent NSCLC 53 fibrosis 53 HER2 negative 53 white matter hyperintensities 53 endosonography 53 node metastasis 53 lateral radiograph 53 HbA1c levels 53 colorectal neoplasms 53 postoperative complications 53 Multivariate analysis revealed 53 total knee arthroplasty 53 axillary node 53 aromatase inhibitors AIs 53 DNA methylation patterns 53 neurologic progression 53 pituitary adenomas 53 secondary hyperparathyroidism 53 resection 53 pulmonary arterial 53 gene expression patterns 53 serum lipid levels 53 serum creatinine 53 tumor xenograft models 53 childhood acute lymphoblastic 53 dimensional echocardiography 53 interrater reliability 53 Endothelial dysfunction 53 neurologic complications 53 hematuria 53 Score TOS 53 Comorbidities 53 invasive carcinomas 53 antioxidant supplementation 53 concomitant medications 53 left ventricular LV 53 transitional cell carcinoma 53 Cognitive impairment 53 KIF6 carriers 53 benign lesions 53 axillary dissection 53 MTHFR 53 radiographically 53 airway responsiveness 53 UGT#A# * 53 apolipoproteins 53 invasive ductal 53 genomic alterations 53 elevated ALT 53 hemoglobin Hb 53 varices 53 microbleeds 53 endoscopic ultrasonography 53 surgical debulking 53 lung resections 53 transthoracic 53 randomized controlled trials RCTs 53 Rating Scale BPRS 53 transesophageal echocardiography 53 SRBD 53 baroreflex 53 acetabular fractures 53 TNFalpha 53 DMARD therapy 53 colorectal cancer CRC 53 relapsed AML